(VIANEWS) – ProLogis (PLD), Bank OZK (OZK), Entravision Communications Corporation (EVC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. ProLogis (PLD)
51.9% sales growth and 5.91% return on equity
Prologis, Inc. is the global leader in logistics real estate with a focus on high-barrier, high-growth markets. At March 31, 2023, the company owned or had investments in, on a wholly owned basis or through co-investment ventures, properties and development projects expected to total approximately 1.2 billion square feet (113 million square meters) in 19 countries. Prologis leases modern logistics facilities to a diverse base of approximately 6,600 customers principally across two major categories: business-to-business and retail/online fulfillment.
Earnings Per Share
As for profitability, ProLogis has a trailing twelve months EPS of $3.21.
PE Ratio
ProLogis has a trailing twelve months price to earnings ratio of 39.64. Meaning, the purchaser of the share is investing $39.64 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 5.91%.
Sales Growth
ProLogis’s sales growth is 54.6% for the ongoing quarter and 51.9% for the next.
Yearly Top and Bottom Value
ProLogis’s stock is valued at $127.25 at 16:22 EST, below its 52-week high of $138.86 and way higher than its 52-week low of $98.03.
2. Bank OZK (OZK)
22.5% sales growth and 12.72% return on equity
Bank OZK provides various retail and commercial banking services. The company accepts various deposit products, including non-interest bearing checking, interest bearing transaction, business sweep, savings, money market, individual retirement, and other accounts, as well as time deposits. It also offers real estate, consumer and business purpose, indirect recreational vehicle and marine, commercial and industrial, government guaranteed, agricultural, small business, homebuilder, and affordable housing loans; business aviation and subscription financing services; and mortgage and other lending products. The company also provides trust and wealth services, such as personal, custodial, investment management, and retirement accounts, as well as corporate trust services comprising trustee, paying and registered transfer agent, and other incidental services. In addition, it offers treasury management services comprising automated clearing house, wire transfer, transaction reporting, wholesale lockbox, remote deposit capture, automated credit line transfer, reconciliation, positive pay, and merchant and commercial card services, as well as zero balance and investment sweep accounts. Further, the company provides ATMs; telephone, online, and mobile banking services; debit and credit cards; safe deposit boxes; and other products and services, as well as processes merchant debit and credit card transactions. As of December 31, 2020, it operated approximately 250 offices in Arkansas, Georgia, Florida, North Carolina, Texas, South Carolina, California, New York, and Mississippi. The company was formerly known as Bank of the Ozarks and changed its name to Bank OZK in July 2018. Bank OZK was founded in 1903 and is headquartered in Little Rock, Arkansas.
Earnings Per Share
As for profitability, Bank OZK has a trailing twelve months EPS of $4.46.
PE Ratio
Bank OZK has a trailing twelve months price to earnings ratio of 8.91. Meaning, the purchaser of the share is investing $8.91 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 12.72%.
Moving Average
Bank OZK’s value is higher than its 50-day moving average of $36.69 and under its 200-day moving average of $40.25.
Revenue Growth
Year-on-year quarterly revenue growth grew by 21.8%, now sitting on 1.21B for the twelve trailing months.
3. Entravision Communications Corporation (EVC)
16.1% sales growth and 7.42% return on equity
Entravision Communications Corporation operates as an advertising, media, and technology solutions company worldwide. The company operates through three segments: Digital, Television, and Audio. It reaches and engages Hispanics across acculturation levels and media channels. The company's portfolio encompasses integrated end-to-end advertising solutions, including digital, television, and audio properties. It also offers a suite of end-to-end digital advertising solutions, including digital commercial partnerships services, as well as advertising customers billing and technological and other support services, including strategic marketing and training; and Smadex, a programmatic ad purchasing platform that enables advertising customers or ad agencies to purchase advertising electronically and manage data-driven advertising campaigns through online marketplaces. In addition, the company provides a branding and mobile performance solutions, such as managed services to advertisers looking to connect with consumers on mobile devices; and digital audio advertising solutions for advertisers. Further, it sells advertisements and syndicated radio programming solutions through its Entravision radio network. As of March 3, 2022, the company had 50 television stations; and 46 Spanish-language radio stations. It serves advertisers from various industries, such as e-commerce, retail, entertainment, gaming, delivery services, financial technology, communications, lifestyle, and travel. The company was founded in 1996 and is headquartered in Santa Monica, California.
Earnings Per Share
As for profitability, Entravision Communications Corporation has a trailing twelve months EPS of $0.21.
PE Ratio
Entravision Communications Corporation has a trailing twelve months price to earnings ratio of 21.71. Meaning, the purchaser of the share is investing $21.71 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 7.42%.
Volume
Today’s last reported volume for Entravision Communications Corporation is 495771 which is 15.11% above its average volume of 430693.
Revenue Growth
Year-on-year quarterly revenue growth grew by 21.2%, now sitting on 998.04M for the twelve trailing months.
4. PACCAR (PCAR)
13.8% sales growth and 24.17% return on equity
PACCAR Inc designs, manufactures, and distributes light, medium, and heavy-duty commercial trucks in the United States, Europe, Mexico, South America, Australia, and internationally. It operates through three segments: Truck, Parts, and Financial Services. The Truck segment designs, manufactures, and distributes trucks for the over-the-road and off-highway hauling of commercial and consumer goods. It sells its trucks through a network of independent dealers under the Kenworth, Peterbilt, and DAF nameplates. The Parts segment distributes aftermarket parts for trucks and related commercial vehicles. The Financial Services segment conducts full-service leasing operations under the PacLease trade name, as well as provides finance and leasing products and services to customers and dealers. This segment also offers equipment financing and administrative support services for its franchisees; retail loan and leasing services for small, medium, and large commercial trucking companies, as well as independent owners/operators and other businesses; and truck inventory financing services to independent dealers. In addition, this segment offers loans and leases directly to customers for the acquisition of trucks and related equipment. The company also manufactures and markets industrial winches under the Braden, Carco, and Gearmatic nameplates. PACCAR Inc was founded in 1905 and is headquartered in Bellevue, Washington.
Earnings Per Share
As for profitability, PACCAR has a trailing twelve months EPS of $6.
PE Ratio
PACCAR has a trailing twelve months price to earnings ratio of 14.21. Meaning, the purchaser of the share is investing $14.21 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.17%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 30.9%, now sitting on 30.82B for the twelve trailing months.
Previous days news about PACCAR(PCAR)
- According to Zacks on Thursday, 13 July, "At the CES 2023, Transportation Hall, PACCAR displayed a battery-powered Peterbilt 579EV, a hydrogen fuel-cell Kenworth T680E and a Peterbilt autonomous Model 579. ", "Yesterday, two auto players, trucking giant PACCAR (PCAR Quick QuotePCAR – Free Report) and leading truck engine maker Cummins (CMI Quick QuoteCMI – Free Report) announced payout hikes. "
- According to Zacks on Thursday, 13 July, "A few better-ranked players in the auto space include Ford (F Quick QuoteF – Free Report) , PACCAR (PCAR Quick QuotePCAR – Free Report) and Group 1 Automotive (GPI Quick QuoteGPI – Free Report) . "
5. Halozyme Therapeutics (HALO)
6.4% sales growth and 111.4% return on equity
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its flagship product is Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in subcutaneous urography and to improve resorption of radiopaque agents. The company also develops Perjeta; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; Horizon Therapeutics plc; National Institute of Allergy and Infectious Diseases; Centre for the AIDS Programme of Research in South Africa; and ViiV Healthcare Limited for small and large molecule targets for the treatment and prevention of HIV. Halozyme Therapeutics, Inc. was founded in 1998 and is based in San Diego, California.
Earnings Per Share
As for profitability, Halozyme Therapeutics has a trailing twelve months EPS of $1.3.
PE Ratio
Halozyme Therapeutics has a trailing twelve months price to earnings ratio of 27.75. Meaning, the purchaser of the share is investing $27.75 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 111.4%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 18.9% and a drop 1.4% for the next.
